Keryx Biopharmaceuticals, Inc. to Present at the Stifel 2014 Healthcare Conference

NEW YORK, Nov. 14, 2014 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) today announced that Ron Bentsur, the Company's Chief Executive Officer, will present a corporate overview at the Stifel 2014 Healthcare Conference taking place November 18-19 in New York City.

Mr. Bentsur's presentation will take place on Tuesday, November 18, at 10:20 a.m. ET.

A live audio webcast of Mr. Bentsur's presentation will be accessible within the Investor Relations section of the Company's website at http://investors.keryx.com. An archived version of this webcast will be available following the conclusion of the live presentation.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals, headquartered in New York, is focused on bringing innovative therapies to market for patients with renal disease. The Company's lead product, Ferric Citrate, was approved by the U.S. Food and Drug Administration on September 5, 2014.

For additional company information, including full prescribing information for Ferric Citrate, please visit www.keryx.com.

CONTACT: KERYX CONTACT: Amy Sullivan Vice President, Corporate Development and Public Affairs Tel: 617.466.3447 e-mail: amy.sullivan@keryx.com

Source:Keryx Biopharmaceuticals, Inc.